(19)
(11) EP 3 519 827 A1

(12)

(43) Date of publication:
07.08.2019 Bulletin 2019/32

(21) Application number: 17791768.9

(22) Date of filing: 26.09.2017
(51) International Patent Classification (IPC): 
G01N 33/574(2006.01)
G01N 33/92(2006.01)
C07K 16/28(2006.01)
(86) International application number:
PCT/US2017/053370
(87) International publication number:
WO 2018/064013 (05.04.2018 Gazette 2018/14)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 27.09.2016 US 201662400589 P
11.10.2016 US 201662406727 P
03.04.2017 US 201762480994 P
17.05.2017 US 201762507580 P

(71) Applicant: Oncologie, Inc.
Waltham, MA 02451 (US)

(72) Inventors:
  • TANG, Min
    Tustin, CA 92780 (US)
  • SHAN, Joseph, S.
    Tustin, CA 92780 (US)
  • KING, Steven,W.
    Tustin, CA 92780 (US)
  • CHANG, Connie
    Tustin, CA 92780 (US)
  • BROWN, Michael, A.
    Tustin, CA 92780 (US)

(74) Representative: Miller, David James et al
Mathys & Squire LLP The Shard 32 London Bridge Street
London SE1 9SG
London SE1 9SG (GB)

   


(54) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF 2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR